Chardan Capital reiterated coverage on Axcella Health with a new price target

11/16/21 9:26:58 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Chardan Capital reiterated coverage of Axcella Health with a rating of Buy and set a new price target of $12.00 from $10.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AXLA

Date	Price Target	Rating	Analyst
11/16/2021	$10.00 → $12.00	Buy	Chardan Capital
10/12/2021	$6.00	Outperform	Noble Capital Markets
9/22/2021	$9.00 → $5.00	Buy → Neutral	Goldman Sachs
7/30/2021		Neutral → Underweight	JP Morgan
7/6/2021	$14.00	Buy	HC Wainwright & Co.